Current and future treatment approaches for neuromyelitis optica.
about
Aquaporin 4 and neuromyelitis opticaAn update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesInflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis OpticaUpdate on neuromyelitis optica: natural history and management.Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat modelCurrent options for the treatment of optic neuritis.Seronegative neuromyelitis optica after cardiac transplantation.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels.Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinaseImmunological follow-up of patients with neuromyelitis optica: is there a good biomarker?The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?Sex disparities in neuro-ophthalmologic disorders.Acquired pathology of the pediatric spine and spinal cord.Th17 cells in neuromyelitis optica spectrum disorder: a review.Neuromyelitis Optica (Devic's Syndrome): an Appraisal.Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica.Plasma exchange for steroid unresponsive Devic's disease.Life on hold: the experience of living with neuromyelitis optica.Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections.Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party.Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China.Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica
P2860
Q24613666-64455699-C259-4673-80E8-75C391C3980BQ26748601-03B38819-9469-4A14-90BD-B8DB77F41932Q26767391-4CFE7752-EECA-401A-AFB1-0456273B01ABQ31160004-54B4F77B-60CE-48EF-AC31-03E1EB05E73CQ33702126-32908C43-B6EC-47FB-B9A7-B66511BB0CDEQ34142474-058DC072-8A3F-4527-BA38-976B3C8275AAQ36173222-9537153D-7323-422A-9B06-9815925BE64AQ36368530-E5AB101F-FFA5-4B97-85E5-9F1238315006Q36528736-5AC4C69D-BDEB-4C85-95D1-F9A6F3C3601DQ36596808-E8027008-431C-4CEC-A6F4-863523C60C37Q36852554-7CA599D6-366A-4CEA-B08E-AD86799D4FCBQ38061621-779C5487-4C58-4378-AAFA-1236042B974AQ38130899-A53BD9C7-2EFD-461D-B3AA-6DEC52D720D6Q38152822-729CDB1D-7A84-4FAD-97A7-0607250139D4Q38218704-EF9E80BA-65F9-461E-8AAE-87921AD67465Q38582356-384FF865-8507-48E8-988C-ABF91C4809D0Q38765404-868D192A-7182-4713-8882-8B6364E11276Q38893206-9EC94138-C323-4580-9335-DBA16C005F03Q42143005-865C031F-2BBD-4BCA-AF90-CB18351CAB69Q43246789-6A9481F4-D325-4AD0-9BCC-C56DAACD5C56Q44299516-F3ABB089-CB95-4A7B-BA22-C094E1FCABFEQ45018598-8F41A9B3-7323-42DC-99AF-5F4F0B755CACQ45867293-12474D2F-935B-4BCB-A04F-9749AF3EE77CQ47555447-B84570E2-F2BC-41FF-A346-5454C0626BA5Q47927193-41275593-E2FC-4BF1-861A-1604DF10D624Q57267894-5731D0AC-761E-4839-ACD0-B1977217312C
P2860
Current and future treatment approaches for neuromyelitis optica.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and future treatment approaches for neuromyelitis optica.
@en
Current and future treatment approaches for neuromyelitis optica.
@nl
type
label
Current and future treatment approaches for neuromyelitis optica.
@en
Current and future treatment approaches for neuromyelitis optica.
@nl
prefLabel
Current and future treatment approaches for neuromyelitis optica.
@en
Current and future treatment approaches for neuromyelitis optica.
@nl
P2860
P356
P1476
Current and future treatment approaches for neuromyelitis optica.
@en
P2093
Jérôme de Seze
Nicolas Collongues
P2860
P304
P356
10.1177/1756285611398939
P577
2011-03-01T00:00:00Z